Guardant Health Stock Price, News & Analysis

Guardant Health has partnered with the Parker Institute for Cancer Immunotherapy (PICI) for a research collaboration to study cancer biomarkers and their correlation with immunotherapy responses. This project will analyze patient blood samples from PICI’s RADIOHEAD study, a prospective analysis involving 1,200 participants receiving immune checkpoint inhibitors.

The collaboration aims to enhance understanding of resistance to immune therapies across more than 14 cancer types. Guardant Health will utilize its GuardantINFINITY platform for a multi-dimensional assessment of tumor responses. The findings will contribute to real-world data on immunotherapy outcomes.

Data publication is expected later in 2023, marking a significant step in the development of personalized cancer treatments.

Guardant Health announced that its ECLIPSE Study data will be presented as a late-breaking abstract at Digestive Disease Week (DDW) from May 6-9, 2023, in Chicago. The study focuses on the performance of the Shield blood test for early-stage colorectal cancer detection in asymptomatic patients. Co-CEO AmirAli Talasaz emphasized the test's potential to increase screening rates, which remain low despite existing modalities. Gastroenterologist Daniel Chung also highlighted the need for less invasive screening methods. The acceptance of the ECLIPSE Study signifies a robust research effort, and further data will be shared during the conference. Guardant Health aims to improve adherence to cancer screening through its innovative technologies.

Guardant Health, a precision oncology company, will report its Q1 2023 financial results on May 9, 2023, after market close. A conference call will be hosted at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can access the live webcast on the company’s website, with an archive available afterward. Guardant Health focuses on innovative cancer testing solutions, including the Guardant360 and Shield tests, aimed at improving patient outcomes and reducing healthcare costs.

Guardant Health (Nasdaq: GH) announced that the Guardant360 Response test is now covered for U.S. Medicare patients with metastatic or inoperable solid tumors undergoing immune checkpoint inhibitor therapy. This coverage allows for monitoring molecular response through circulating tumor DNA (ctDNA) changes, providing early indications of treatment effectiveness. Patients will receive the Guardant360 CDx or LDT test to establish a ctDNA baseline before therapy and a Guardant360 Response test 4 to 10 weeks post-initiation to assess changes. This significant policy expansion follows previous Medicare coverages for other Guardant Health tests, enhancing the company's offerings and supporting oncologists in making informed treatment decisions.

Guardant Health (NASDAQ: GH) announced it will present data from 14 studies at the 2023 AACR Annual Meeting in Orlando, Florida, from April 14-19. The studies focus on the capabilities of the GuardantINFINITY™ platform in precision oncology, particularly through epigenomic analysis and methylation sequencing for biomarker discovery and therapy selection.

Chairman and co-CEO, Helmy Eltoukhy, highlighted that the research demonstrates the importance of understanding the tumor microenvironment. The GuardantINFINITY platform shows advantages in monitoring circulating tumor DNA (ctDNA) with enhanced sensitivity compared to traditional methods. Several studies underscore its potential in minimal residual disease detection and more.